Neoleukin Therapeutics Current Valuation vs. Price To Book
NLTXDelisted Stock | USD 0.69 0.01 1.43% |
For Neoleukin Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neoleukin Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neoleukin Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neoleukin Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neoleukin Therapeutics over time as well as its relative position and ranking within its peers.
Neoleukin |
Neoleukin Therapeutics Price To Book vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neoleukin Therapeutics's current stock value. Our valuation model uses many indicators to compare Neoleukin Therapeutics value to that of its competitors to determine the firm's financial worth. Neoleukin Therapeutics is rated below average in current valuation category among its peers. It also is rated below average in price to book category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neoleukin Therapeutics' earnings, one of the primary drivers of an investment's value.Neoleukin Current Valuation vs. Competition
Neoleukin Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 409.4 Million. Neoleukin Therapeutics has negative current valuation of (35.02 Million) having no influence on the industry.
Neoleukin Price To Book vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Neoleukin Therapeutics |
| = | (35.02 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Neoleukin Therapeutics |
| = | 0.44 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Neoleukin Price To Book Comparison
Neoleukin Therapeutics is currently under evaluation in price to book category among its peers.
Neoleukin Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Neoleukin Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neoleukin Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Neoleukin Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Neoleukin Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Neoleukin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neoleukin Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neoleukin Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neoleukin Therapeutics' important profitability drivers and their relationship over time.
Use Neoleukin Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neoleukin Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neoleukin Therapeutics will appreciate offsetting losses from the drop in the long position's value.Neoleukin Therapeutics Pair Trading
Neoleukin Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Neoleukin Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neoleukin Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neoleukin Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neoleukin Therapeutics to buy it.
The correlation of Neoleukin Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neoleukin Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neoleukin Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neoleukin Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Neoleukin Therapeutics position
In addition to having Neoleukin Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Volatility ETFs Thematic Idea Now
Volatility ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |